Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP. de Groot FA, et al. Among authors: posthuma efm. Eur J Cancer. 2024 Dec;213:115068. doi: 10.1016/j.ejca.2024.115068. Epub 2024 Oct 13. Eur J Cancer. 2024. PMID: 39427440 Free article.
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Huls G, Chitu DA, Tick L, Boersma R, Breems D, Herbers A, Klein SK, de Jonge S, Westerweel PE, Cruijsen M, Hoogendoorn M, Cuijpers M, Deeren D, Bailly B, Visser O, van Rhenen A, Posthuma EFM, Valk PJM, Cloos J, Ammatuna E, Refos JM, Fakkert R, Löwenberg B, Ossenkoppele GJ. Huls G, et al. Among authors: posthuma efm. Ann Hematol. 2024 Oct 5. doi: 10.1007/s00277-024-06033-y. Online ahead of print. Ann Hematol. 2024. PMID: 39367118
Health care utilization up to 11 years after diagnosis among patients with a hematologic malignancy and its association with socioeconomic position.
Ekels A, van de Poll-Franse LV, Issa DE, Oosterveld M, van der Griend R, Hoogendoorn M, Koster A, Nijziel MR, Arts LPJ, Posthuma EFM, Oerlemans S. Ekels A, et al. Among authors: posthuma efm. J Cancer Surviv. 2024 Sep 17. doi: 10.1007/s11764-024-01676-2. Online ahead of print. J Cancer Surviv. 2024. PMID: 39287915
Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.
Ekels A, van de Poll-Franse LV, Issa DE, Hoogendoorn M, Nijziel MR, Koster A, de Jong CN, Achouiti A, Thielen N, Tick LW, Te Boome LCJ, Bohmer LH, Tiren-Verbeet NL, Veldhuis GJ, de Boer F, van der Klift M, Posthuma EFM, Oerlemans S. Ekels A, et al. Among authors: posthuma efm. Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06006-1. Online ahead of print. Ann Hematol. 2024. PMID: 39279019
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Fürstenau M, et al. Among authors: posthuma efm. Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Free article. Clinical Trial.
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
Efficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, Chantepie S, Griskevicius L, Neubauer A, Audisio E, Luppi M, Fuhrmann S, Foà R, Crysandt M, Gaidano G, Vrhovac R, Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O, Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls G, Lübbert M. Efficace F, et al. Among authors: posthuma efm. Blood. 2024 Aug 1;144(5):541-551. doi: 10.1182/blood.2023023625. Blood. 2024. PMID: 38717861 Free article. Clinical Trial.
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: posthuma efm. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200/JCO.23.01386. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38359378 Free PMC article.
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM, Neppelenbroek SIM, Aleman BMP, Janus CPM, Krol ADG, van Spronsen DJ, Plattel WJ, Roesink JM, Verschueren KMS, Zijlstra JM, Koene HR, Nijziel MR, Schimmel EC, de Jongh E, Ong F, Te Boome LCJ, van Rijn RS, Böhmer LH, Ta BDP, Visser HPJ, Posthuma EFM, Bilgin YM, Muller K, van Kampen D, So-Osman C, Vermaat JSP, de Weijer RJ, Kersten MJ, van Leeuwen FE, Schaapveld M. Geurts YM, et al. Among authors: posthuma efm. ESMO Open. 2024 Feb;9(2):102248. doi: 10.1016/j.esmoop.2024.102248. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350338 Free PMC article.
77 results